- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Allergan’s Botox materials referenced “20 licensed indications worldwide” and used the headline “A BIG difference”. PMCPA ruled the worldwide indications framing and…
PMCPA case summary for AUTH/2198/10/9 (Primary Care Trust v Solvay). The provided case text contains no details on allegations, outcome, clauses, or…
A “Dear Pharmacist” tender letter claimed the NPSA “recommends” only licensed ready-to-use injectables. PMCPA said the NPSA expressed a preference and the…
A UK speaker meeting complaint found Daiichi-Sankyo reimbursed a US speaker for drinks likely consumed by accompanying family members. Breach of hospitality…
Sandoz’s German-issued press release referencing NICE guidance was held to be within the UK Code. One statement implying NICE found “no differences”…
Pfizer’s 5‑year budget impact model and ad promoted Xalatan/Xalacom using speculative post‑patent savings and referenced a paediatric programme inconsistent with the SPC.…
Otsuka Europe admitted potential Code issues after confusing affiliate communications on parallel Jinarc SPC variations and an out-of-date package leaflet being packed.…
A pharmacist complained about repeated calls from Astellas reps about formulary approval. The Panel found the pharmacist’s wishes weren’t observed (breach Clauses…
A Seretide Evohaler digital banner in Pulse rotated across 4 frames, but a media agency set frame 2 as a static ‘back-up’.…
A member of the public alleged POM promotional panels at ExCeL London were visible/readable from a public coffee area. Panel found the…
Lilly challenged Roche’s use of “first-line maintenance” for Tarceva across a leavepiece, ad and sponsored feature. Panel found breaches, but the Appeal…
A sponsored HSJ ‘special report’ on atrial fibrillation looked like independent editorial and favoured dronedarone. PMCPA ruled Sanofi-Aventis was inextricably linked to…
A consultant challenged an Asacol leavepiece claiming “up to 72% treatment success”. The Panel found breaches, but on appeal the Appeal Board…
Alcon’s Travatan BAK-free ad used a thornless rose and animal/in vitro data implying better tolerability vs BAK formulation. PMCPA found the ad…
BMJ analysis suggested 3 Ipsen trials were missing EUCTR results. Panel found 2 trials had no UK nexus and 1 was cancelled…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.